DrugBank

AUGUST 20, 2024

The world of drug discovery is in a state of transformation, with advancements in biotechnology opening doors to new possibilities for targeting previously "undruggable" disease mechanisms. You’ll discover real-world examples, such as the transformation of KRAS from an undruggable target to a success story in targeted therapy.

Therapies 72

Therapies Pharmaceuticals Disease Research 72

PPD

MARCH 26, 2024

A large majority of drug developers utilize FSP or hybrid FSP/FSO models, half are “heavy users” Heavy users: Those that use FSP or hybrid FSP/FSO models for most of their clinical development outsourcing. Heavy users leverage these models for nearly three-quarters of their outsourcing.

Clinical Research 98

Clinical Research Clinical Development Pharmaceutical Companies Drug Development 98

The Pharma Data

NOVEMBER 1, 2020

Corlieve is focused on developing novel therapeutics for severe neurological disorders. Corlieve’s lead program employs a novel AAV gene therapy approach for the treatment of refractory temporal lobe epilepsy (TLE), the most commonly diagnosed focal epilepsy in humans. Maryland , US), a leading gene therapy company.

Therapies 52

Therapies Science Treatment Disease 52

Drug Target Review

JUNE 13, 2023

Immerse yourself in exclusive content, including articles on cutting-edge cell line development and insightful interviews with industry experts. Don’t miss your chance to embrace the future of cellular therapies – dive in now! Download your FREE copy today. This eBook is supported by BioTechne.

Engineering 52

Engineering Pharmacy Drug Development Therapies 52

The Pharma Data

DECEMBER 15, 2020

The project also seeks to engage the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) to identify opportunities for regulatory endorsement of such drug development tools. The Diamyd Medical data includes relevant information about disease progression, drug effects and clinical trial design.

Drug Development 40

Drug Development Clinical Trials Trials Vaccine 40

The Pharma Data

DECEMBER 22, 2020

Primary endpoints of this study include safety, tolerability, and tumor response of the ASP-1929 photoimmunotherapy in combination with anti-PD1 therapy. Outside of Japan , Illuminox therapies have not yet been approved as safe or effective by any regulatory authority. SAN MATEO, Calif. , ” About Rakuten Medical, Inc.

Clinical Trials 52

Clinical Trials Therapies Trials Production 52

PPD

OCTOBER 2, 2024

To support these functions, PPD™ Functional Service Partnership (FSP) Clinical Operations solutions harness the full range of innovative technologies, applying extensive skill and expertise to empower our customers to bring therapies to market quickly and within budget.

Clinical Trials 52

Clinical Trials Clinical Development Clinical Research Trials 52

The Pharma Data

SEPTEMBER 17, 2020

17, 2020 /PRNewswire/ — Eli Lilly and Company (NYSE:LLY) and Amgen (NASDAQ:AMGN) today announced a global antibody manufacturing collaboration to significantly increase the supply capacity available for Lilly ‘s potential COVID-19 therapies. View original content to download multimedia: [link]. SOURCE Eli Lilly and Company.

Therapies 52

Therapies Production Government Disease 52

PPD

NOVEMBER 30, 2023

As we approach the end of 2023, it’s time to reflect on the past 12 months and how advances in drug development shaped the pharma and biotech industries. Five Predictions for the Drug Development Industry in 2024 1. Stakeholders across the drug development sphere will unlock the transformative potential of AI.

Clinical Trials 98

Clinical Trials Trials Clinical Research Drug Development 98

PPD

JUNE 17, 2024

Often, however, a hybrid use case will fit into one of these general categories: 1) An existing FSO arrangement needs additional expertise or resources to support a specific study function, requiring the developer to scale or augment that FSO arrangement with FSP services.

Clinical Trials 52

Clinical Trials Clinical Development Trials International 52

The Pharma Data

JANUARY 7, 2021

To view the full announcement, including downloadable images, bios, and more, click here. Key Takeaways: CEO Laurie Heilmann will be presenting the strategic roadmap for accelerating growth of tech-enabled drug discovery in cancer. Click image above to view full announcement.

Pharmaceutical Companies 52

Pharmaceutical Companies Therapies Science Pharmaceuticals 52

Perficient: Drug Development

DECEMBER 31, 2023

Conversational Therapy Your AI Companion At the heart of Youper lies its conversational interface, allowing users to engage in text conversations with an AI-powered assistant. This holistic approach enables users to develop a profound understanding of their mental well-being and fosters a sense of self-awareness.

Therapies 52

Therapies Production 52

The Pharma Data

JANUARY 13, 2021

14, 2021 /PRNewswire/ — MindMed (NEO: MMED), (OTCQB: MMEDF), (DE: MMQ), a leading psychedelic medicine biotech company today announced the addition of Robert Barrow , an accomplished pharmaceutical executive, as Chief Development Officer. We are excited to attract such top tier talent from the psychedelic drug development community.

Clinical Trials 52

Clinical Trials FDA Trials Production 52

Perficient: Drug Development

DECEMBER 22, 2023

Rooted in a holistic approach to mental wellness, “Sanvello” integrates Cognitive Behavioral Therapy (CBT) tools, meditation, and goal-setting into its offerings. The app incorporates CBT tools that empower users to navigate thought patterns, identify cognitive distortions, and develop healthier perspectives.

Therapies 52

Therapies Production 52

Perficient: Drug Development

DECEMBER 22, 2023

Conversational Therapy in Real Time Guiding Through Emotional Challenges Recognizing the prevalence of anxiety and stress in psychological and psychiatric challenges, “Wysa” employs conversational therapy in real-time.

Regulations 52

Regulations Therapies Production 52

PPD

NOVEMBER 21, 2023

The drug development industry is constantly adapting and evolving to bring novel therapeutics to market to improve the lives of patients across the globe. While the drug development industry experienced setbacks during the COVID-19 pandemic, the field  is again gaining momentum reminiscent of its pre-pandemic pace.

Clinical Development 52

Clinical Development Clinical Trials Trials Clinical Research 52

Perficient: Drug Development

AUGUST 20, 2023

Virtual Therapists and Chatbots Online platforms and apps offering virtual therapy sessions or AI-driven chatbots provide accessible and immediate support to individuals who may find traditional therapy challenging or expensive.

Therapies 52

Therapies Production Marketing 52

Perficient: Drug Development

AUGUST 8, 2023

Here are some ways to provide support: Speech Therapy Speech therapy is a specialized field that plays a crucial role in helping individuals overcome speech disabilities and communication challenges.

Therapies 52

Therapies Production Marketing 52

The Pharma Data

JANUARY 20, 2021

21, 2021 /PRNewswire/ — Dynacure , a clinical-stage company focused on developing and commercializing novel therapies to transform the lives of patients with rare diseases who have limited or no treatment options, announced today the appointment of Jean M. View original content to download multimedia: [link].

Treatment 52

Treatment Pharmaceuticals Drug Development Science 52

Perficient: Drug Development

OCTOBER 5, 2023

Therapeutic Benefits : These apps are often used in therapy settings to complement traditional interventions, offering an additional avenue for cognitive development and sensory integration. Sensory Processing Therapy : Offers a range of sensory-based activities and exercises to improve sensory processing skills.

Regulations 52

Regulations Therapies Production Disease 52

PPD

SEPTEMBER 25, 2023

As the clinical trial landscape evolves, drug developers are faced with novel challenges and changes in study recruitment, trial size and structure, and more. The adoption of new innovations, strategies and technologies offers opportunities to address persistent challenges and develop suitable approaches for the future.

Drug Development 104

Drug Development Clinical Trials Drugs Trials 104

The Pharma Data

JANUARY 10, 2021

Food and Drug Administration (FDA) for the initiation of a Phase 1 clinical trial to evaluate IDE397, a small molecule methionine adenosyltransferase 2a (MAT2A) inhibitor, for the treatment of patients having solid tumors with methylthioadenosine phosphorylase (MTAP) deletion. View original content to download multimedia: [link].

FDA 52

FDA Small Molecule Clinical Trials Therapies 52

The Pharma Data

OCTOBER 16, 2020

Paula Brown Stafford, chairman and CEO of Novan, said: “Covid-19 continues to have a major ongoing impact on global health and there remains a direct need for a safe and effective antiviral therapy. Download Medidata’s white paper to learn how to virtualize clinical trials and bring new therapies closer to patients.

Clinical Trials 52

Clinical Trials Trials Pharma Companies Clinical Research 52

The Pharma Data

DECEMBER 14, 2020

The effectiveness of standard therapy with TMZ is limited because the response of GBM to TMZ is dependent upon the expression of the DNA repair enzymatic protein, O 6 -alkylguanine DNA alkyltransferase (MGMT). At the stage of GBM relapse and recurrence, no effective therapy strategies currently exist. Contact.

Clinical Trials 52

Clinical Trials DNA Drugs Therapies 52

The Pharma Data

JANUARY 7, 2021

RMI), a global biotechnology company developing precision-targeted cancer therapies based on its proprietary, anti-cancer treatment platform, Illuminox , will present at the 39th Annual J.P. Outside of Japan, Illuminox therapies have not yet been approved as safe or effective by any regulatory authority. SAN MATEO, Calif. ,

Clinical Trials 52

Clinical Trials Therapies Trials Licensing 52

The Pharma Data

JANUARY 14, 2021

”) platform to transform cancer drug development and identify patients who will benefit from its targeted oncology therapeutics, today announced the pricing of a public offering of 4,285,715 shares of its common stock at a public offering price of $14.00 View original content to download multimedia: [link]. DALLAS , Jan.

Small Molecule 52

Small Molecule Therapies Drug Development Drugs 52

Perficient: Drug Development

AUGUST 1, 2023

Early intervention programs can provide specialized support and therapies to promote development and mitigate potential challenges. Individualized Education Plans (IEPs): For school-age children, individualized education plans (IEPs) can be developed to tailor educational approaches and accommodations to their specific learning needs.

Production 52

Production Therapies 52

Perficient: Drug Development

OCTOBER 5, 2023

Improved Attention : By minimizing distractions, these headphones enhance the user’s ability to pay attention and maintain focus on essential activities, such as studying, working, or participating in therapy sessions.

Production 52

Production Therapies Disease 52

Perficient: Drug Development

SEPTEMBER 26, 2023

While traditional therapies and interventions have proven beneficial, technology, particularly brain training apps, offers a new dimension of support. Challenges Faced by Individuals with Cognitive Disabilities Living with a cognitive disability can present numerous challenges for individuals and their families.

Production 52

Production Disease Therapies Research 52

The Pharma Data

DECEMBER 28, 2020

Scopus is a biopharmaceutical company whose lead drug candidate is a novel, targeted immuno-oncology gene therapy for the treatment of multiple cancers. Dr. Russell has managed all aspects of the drug development and regulatory approval processes for oncology and non-oncology drug candidates. from the Harvard T.H.

Pharmaceuticals 52

Pharmaceuticals Pharmaceutical Companies Government Therapies 52

The Pharma Data

JANUARY 27, 2021

. A total of 15 patients have been recruited to date in the Phase I dose escalation part of the study, all of whom were late stage and have failed conventional treatments, including several lines of rituximab-containing therapies. View original content to download multimedia: [link].

Pharmaceuticals 52

Pharmaceuticals Clinical Trials Licensing Licensing 52

The Pharma Data

DECEMBER 28, 2020

. Moleculin recently announced that the FDA had allowed its request for Investigational New Drug (IND) status for Annamycin, allowing Moleculin to begin a Phase 1B /2 clinical trial in the US for patients with soft tissue sarcoma (STS) that has metastasized to the lungs after first-line therapy for their disease.

FDA 52

FDA Clinical Trials Drugs Pharmaceutical Companies 52

The Pharma Data

NOVEMBER 4, 2020

The pandemic has introduced opportunities in drug development with the creation of Covid-19 vaccines, therapies and diagnostics, but also created challenges in balancing corporate visions with production pipeline. There are several immediate actions to take to serve the workforce and the priority needs of the business: 1.

Science 52

Science Clinical Trials Therapies Laboratories 52

The Pharma Data

OCTOBER 19, 2020

. “Innovation in cancer treatment is realized through collaboration, and the physicians and researchers at Emory’s Winship Cancer Institute have consistently shown their commitment to developing novel cancer therapies using this collaborative approach,” said Chadi Nabhan , M.D., Ramalingam , M.D., Source link.

Clinical Trials 52

Clinical Trials RNA DNA Science 52

The Pharma Data

JANUARY 31, 2021

Trimer-Tag© is an innovative drug development platform which allows the production of novel, covalently-trimerized fusion proteins. Dynavax is a commercial stage biopharmaceutical company developing and commercializing novel vaccines. View original content to download multimedia: [link]. About Trimer-Tag© Technology.

Clinical Trials 52

Clinical Trials Vaccine Trials Virus 52

Perficient: Drug Development

AUGUST 31, 2023

Speech therapy and interventions tailored to the individual’s needs also play a crucial role in improving speech and language skills. Augmentative and Alternative Communication (AAC) devices, speech synthesis technology, and speech recognition tools offer various solutions for overcoming communication barriers.

Production 52

Production Therapies Research Marketing 52

The Pharma Data

DECEMBER 30, 2020

31, 2020 /PRNewswire/ — ImmVira Group Company (“the Company”), a biotechnology platform dedicated to the development of oncolytic virus(“OV”) and vector type approaches to create more effective and safer therapies against cancer, announced today the signing of Series C financing. .

Virus 52

Virus International Trials Clinical Trials 52